arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

download Export Data

Silence Therapeutics plc

SLN

$11.94 ▲ +0.21 (+1.75%) at close

9 Visible periods

25 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Silence Therapeutics plc faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.7B

Dividend Yield —

Revenue Growth -99.1%

Op. Margin None

ROIC -21.2% ↗

FCF / Share $-0.09

Trailing P/E —

Price / Book 12.6x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Aug 7, 2026.

9-Year Financial Trajectory

Quarterly

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$142.00K

↓ -99.1% —

Net Income Profit after all expenses

$-28.53M

↓ -1134.0% —

FCF / Share Free cash flow per share

$-0.09

↓ -25.4% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↑

Cash Quality ↓

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 4 metrics

Metric	Q1 FY2026 Dec 31, 2025 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Dec 31, 2024 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Dec 31, 2024 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Revenue Growth YoY (%)	-99.1% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1339%)	—	—	—	—	—	—	—	—
EPS Growth YoY (%)	-900.0% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—	—	—	—	—
Net Income Growth YoY (%)	-1134.0% Weak Weak Year-over-year change in net income	—	—	—	—	—	—	—	—
FCF Growth YoY (%)	-25.4% Weak Weak Year-over-year change in free cash flow	—	—	—	—	—	—	—	—

💰 Are margins durable? 5 metrics

Metric	Q1 FY2026 Dec 31, 2025 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Dec 31, 2024 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Dec 31, 2024 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Operating Margin (%) (%)	—	—	—	—	-35.6% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-337%)	—	—	—	—
Effective Tax Rate (%) (%)	0.0% Excellent ↓ Excellent Declining Actual taxes paid relative to pre-tax income Optimal: 15-25%	1.6% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-0.1% Excellent ↑ Excellent Improving Actual taxes paid relative to pre-tax income Optimal: 15-25%	-1.2% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	-11.8% Excellent Excellent Actual taxes paid relative to pre-tax income Optimal: 15-25%	—	—	—	—
Profit Margin (%) (%)	—	—	-154.3% Weak → Weak Stable Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-1386%)	-305.8% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-2649%)	-14.7% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-223%)	—	—	—	—
FCF Margin (%) (%)	—	127.7% Excellent Excellent Free cash flow as a percentage of revenue Optimal: > 10%	—	—	-58.2% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—	—	—
FCF / Net Income (x)	0.43x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	0.72x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	11.10x Excellent ↑ Excellent Improving Free cash flow relative to reported net income Optimal: > 1x	2.38x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	3.95x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	—	—	—	—

🎯 Is capital allocation efficient? 3 metrics

Metric	Q1 FY2026 Dec 31, 2025 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Dec 31, 2024 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Dec 31, 2024 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Return on Invested Capital (%)	-21.2% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-50.7% Weak ↑ Weak Improving Return earned on debt + equity capital invested Optimal: > 10%	-136.6% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-107.6% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	-28.4% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	—	—	—	—
Return on Capital (%) (%)	-21.6% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-24.4% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-14.8% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-11.5% Weak Weak Operating profit relative to total assets Optimal: > 10%	-2.8% Weak Weak Operating profit relative to total assets Optimal: > 10%	—	—	—	—
Return on Common Equity (%) (%)	-21.3% Weak ↑ Weak Improving Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-242%)	-49.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-432%)	-10.5% Weak → Weak Stable Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-170%)	-10.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-170%)	-10.5% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-170%)	—	—	—	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	Q1 FY2026 Dec 31, 2025 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Dec 31, 2024 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Dec 31, 2024 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Net Debt (USD)	$-11.28M	$-11.28M	$-121.33M	$-121.33M	$-121.33M	$-121.33M	$-68.79M	—	—

📊 What does each share earn? 6 metrics

Metric	Q1 FY2026 Dec 31, 2025 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Dec 31, 2024 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Dec 31, 2024 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Revenue per Share (USD)	$0.00	—	$0.01	$0.01	$0.12	—	—	—	—
Basic EPS, GAAP (USD)	$-0.20	$-0.21	$-0.25	$-0.14	$-0.02	—	—	—	—
Free Cash Flow per Share (USD)	$-0.09	—	$-0.18	$-0.04	$-0.07	—	—	—	—
Book Value per Share (USD)	$0.95	$0.44	$0.19	$0.19	$0.19	$0.95	$0.19	$0.25	—
Tangible Book Value per Share (USD)	$0.88	$0.36	$0.10	$0.10	$0.11	$0.88	$0.10	$0.16	—
Basic Weighted Avg Shares (shares)	141.68M	—	141.20M	140.21M	131.88M	—	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	Q1 FY2026 Dec 31, 2025 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Dec 31, 2024 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Dec 31, 2024 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Working Capital (USD)	$105.05M	$105.05M	$170.54M	$170.54M	$170.54M	$170.54M	$80.81M	—	—
Total Equity (USD)	$134.02M	$62.30M	$21.99M	$21.99M	$21.99M	$134.02M	$21.99M	$27.22M	$12.37M

📋 What is driving earnings? 4 metrics

Metric	Q1 FY2026 Dec 31, 2025 10-Q ↗	Q4 FY2025 Dec 31, 2025 10-K ↗	Q3 FY2025 Dec 31, 2024 10-Q ↗	Q2 FY2025 Dec 31, 2024 10-Q ↗	Q1 FY2025 Dec 31, 2024 10-Q ↗	Q4 FY2024 Dec 31, 2024 10-K ↗	Q4 FY2023 Dec 31, 2023 10-K ↗	Q4 FY2022 Dec 31, 2022 10-K ↗	Q4 FY2021 Dec 31, 2021 10-K ↗
Sales/Revenue/Turnover (USD)	$142.00K	$-17.39M	$1.50M	$756.00K	$15.70M	—	—	—	—
Depreciation Expense (USD)	$73.00K	$52.00K	$86.00K	$86.00K	$88.00K	—	—	—	—
Net Income, GAAP (USD)	$-28.53M	$-31.00M	$-2.31M	$-2.31M	$-2.31M	—	—	—	—
Operating Cash Flow (USD)	$-12.31M	$-22.11M	$-25.61M	$-5.41M	$-9.14M	—	—	—	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 5 years · 9 quarters

Silence Therapeutics plc

Analytical Summary

9-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare SLN with peers